Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1988 Apr;32(4):530–534. doi: 10.1128/aac.32.4.530

Pharmacokinetics of imipenem-cilastatin in patients with renal insufficiency undergoing continuous ambulatory peritoneal dialysis.

P Somani 1, E H Freimer 1, M L Gross 1, J T Higgins Jr 1
PMCID: PMC172215  PMID: 3377464

Abstract

In six patients with end-stage renal disease, a single bolus of imipenem-cilastatin (500 mg each) was given either intravenously or intraperitoneally in a randomized crossover protocol such that each patient received the drug by both routes at a 2- to 3-week interval. Drug levels in plasma and the peritoneal dialysis fluid were analyzed at frequent intervals, and various pharmacokinetic variables were calculated for a one-compartment open model. Data obtained in the present study suggest that while no significant difference in peak plasma levels or volume of distribution were noted, the following variables were significantly different for imipenem as compared with cilastatin: elimination half-life, total plasma clearance, area under the concentration-time curve, and percent drug excretion in the peritoneal dialysis fluid. The elimination half-life of imipenem (3.28 h) or cilastatin (8.84 h) in our patients was in the same range as observed in patients with minimal renal function undergoing hemodialysis. The dose of imipenem-cilastatin should be reduced appropriately in patients with end-stage renal disease undergoing peritoneal dialysis.

Full text

PDF
530

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albin H. C., Demotes-Mainard F. M., Bouchet J. L., Vincon G. A., Martin-Dupont C. Pharmacokinetics of intravenous and intraperitoneal cefotaxime in chronic ambulatory peritoneal dialysis. Clin Pharmacol Ther. 1985 Sep;38(3):285–289. doi: 10.1038/clpt.1985.172. [DOI] [PubMed] [Google Scholar]
  2. Bennett W. M., Aronoff G. R., Morrison G., Golper T. A., Pulliam J., Wolfson M., Singer I. Drug prescribing in renal failure: dosing guidelines for adults. Am J Kidney Dis. 1983 Nov;3(3):155–193. doi: 10.1016/s0272-6386(83)80060-2. [DOI] [PubMed] [Google Scholar]
  3. Berman S. J., Sugihara J. G., Nakamura J. M., Kawahara K. K., Wong E. G., Musgrave J. E., Wong L. M., Siemsen A. M. Multiple-dose study of imipenem/cilastatin in patients with end-stage renal disease undergoing long-term hemodialysis. Am J Med. 1985 Jun 7;78(6A):113–116. doi: 10.1016/0002-9343(85)90112-3. [DOI] [PubMed] [Google Scholar]
  4. Bunke C. M., Aronoff G. R., Brier M. E., Sloan R. S., Luft F. C. Cefazolin and cephalexin kinetics in continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther. 1983 Jan;33(1):66–72. doi: 10.1038/clpt.1983.9. [DOI] [PubMed] [Google Scholar]
  5. Bunke C. M., Aronoff G. R., Brier M. E., Sloan R. S., Luft F. C. Tobramycin kinetics during continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther. 1983 Jul;34(1):110–116. doi: 10.1038/clpt.1983.138. [DOI] [PubMed] [Google Scholar]
  6. Demetriades J. L., Souder P. R., Entwistle L. A., Vincek W. C., Musson D. G., Bayne W. F. High-performance liquid chromatographic determination of cilastatin in biological fluids. J Chromatogr. 1986 Oct 31;382:225–231. doi: 10.1016/s0378-4347(00)83520-3. [DOI] [PubMed] [Google Scholar]
  7. Drusano G. L., Standiford H. C. Pharmacokinetic profile of imipenem/cilastatin in normal volunteers. Am J Med. 1985 Jun 7;78(6A):47–53. doi: 10.1016/0002-9343(85)90101-9. [DOI] [PubMed] [Google Scholar]
  8. Gibson T. P., Demetriades J. L., Bland J. A. Imipenem/cilastatin: pharmacokinetic profile in renal insufficiency. Am J Med. 1985 Jun 7;78(6A):54–61. doi: 10.1016/0002-9343(85)90102-0. [DOI] [PubMed] [Google Scholar]
  9. Gross M. L., Somani P., Ribner B. S., Raeader R., Freimer E. H., Higgins J. T., Jr Ceftizoxime elimination kinetics in continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther. 1983 Nov;34(5):673–680. doi: 10.1038/clpt.1983.231. [DOI] [PubMed] [Google Scholar]
  10. Janicke D. M., Morse G. D., Apicella M. A., Jusko W. J., Walshe J. J. Pharmacokinetic modeling of bidirectional transfer during peritoneal dialysis. Clin Pharmacol Ther. 1986 Aug;40(2):209–218. doi: 10.1038/clpt.1986.165. [DOI] [PubMed] [Google Scholar]
  11. Keller E., Jansen A., Pelz K., Hoppe-Seyler G., Schollmeyer P. Intraperitoneal and intravenous cefoperazone kinetics during continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther. 1984 Feb;35(2):208–213. doi: 10.1038/clpt.1984.28. [DOI] [PubMed] [Google Scholar]
  12. Morse G. D., Lane T., Nairn D. K., Deterding J., Curry J., Gal P. Peritoneal transport of cefonicid. Antimicrob Agents Chemother. 1987 Feb;31(2):292–294. doi: 10.1128/aac.31.2.292. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Morse G., Janicke D., Cafarell R., Piontek K., Apicella M., Jusko W. J., Walshe J. Moxalactam epimer disposition in patients undergoing continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther. 1985 Aug;38(2):150–156. doi: 10.1038/clpt.1985.151. [DOI] [PubMed] [Google Scholar]
  14. Norrby S. R., Rogers J. D., Ferber F., Jones K. H., Zacchei A. G., Weidner L. L., Demetriades J. L., Gravallese D. A., Hsieh J. Y. Disposition of radiolabeled imipenem and cilastatin in normal human volunteers. Antimicrob Agents Chemother. 1984 Nov;26(5):707–714. doi: 10.1128/aac.26.5.707. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Paton T. W., Cornish W. R., Manuel M. A., Hardy B. G. Drug therapy in patients undergoing peritoneal dialysis. Clinical pharmacokinetic considerations. Clin Pharmacokinet. 1985 Sep-Oct;10(5):404–425. doi: 10.2165/00003088-198510050-00003. [DOI] [PubMed] [Google Scholar]
  16. Petersen J., Stewart R. D., Catto G. R., Edward N. Pharmacokinetics of intraperitoneal cefotaxime treatment of peritonitis in patients on continuous ambulatory peritoneal dialysis. Nephron. 1985;40(1):79–82. doi: 10.1159/000183433. [DOI] [PubMed] [Google Scholar]
  17. Prowant B., Nolph K., Ryan L., Twardowski Z., Khanna R. Peritonitis in continuous ambulatory peritoneal dialysis: analysis of an 8-year experience. Nephron. 1986;43(2):105–109. doi: 10.1159/000183807. [DOI] [PubMed] [Google Scholar]
  18. Rogers J. D., Meisinger M. A., Ferber F., Calandra G. B., Demetriades J. L., Bland J. A. Pharmacokinetics of imipenem and cilastatin in volunteers. Rev Infect Dis. 1985 Jul-Aug;7 (Suppl 3):S435–S446. doi: 10.1093/clinids/7.supplement_3.s435. [DOI] [PubMed] [Google Scholar]
  19. Rubin J., Rogers W. A., Taylor H. M., Everett E. D., Prowant B. F., Fruto L. V., Nolph K. D. Peritonitis during continuous ambulatory peritoneal dialysis. Ann Intern Med. 1980 Jan;92(1):7–13. doi: 10.7326/0003-4819-92-1-7. [DOI] [PubMed] [Google Scholar]
  20. Singlas E., Boutron H. F., Merdjan H., Brocard J. F., Pocheville M., Fries D. Moxalactam kinetics during chronic ambulatory peritoneal dialysis. Clin Pharmacol Ther. 1983 Sep;34(3):403–407. doi: 10.1038/clpt.1983.187. [DOI] [PubMed] [Google Scholar]
  21. Somani P., Shapiro R. S., Stockard H., Higgins J. T. Unidirectional absorption of gentamicin from the peritoneum during continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther. 1982 Jul;32(1):113–121. doi: 10.1038/clpt.1982.134. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES